Home Auto Tech Carisma’s First Results from In Vivo CAR-M Collaboration with Moderna to be Unveiled at SITC 2023

Carisma’s First Results from In Vivo CAR-M Collaboration with Moderna to be Unveiled at SITC 2023

0
Carisma’s First Results from In Vivo CAR-M Collaboration with Moderna to be Unveiled at SITC 2023

Late-breaking Pre-clinical Data to be Presented at SITC 38th Annual Meeting

Carisma Therapeutics Inc. (Nasdaq: CARM) is set to present new pre-clinical data at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, which will be held from November 1 to November 5, 2023, in San Diego, California. The data includes research leveraging an mRNA platform to develop in-vivo chimeric antigen receptor macrophages (CAR-M). The study aims to explore the potential for an off-the-shelf treatment approach to enhance therapeutic benefit for cancer patients.

The first presentation, titled “In vivo CAR-M: Redirecting endogenous myeloid cells with mRNA for cancer immunotherapy,” will be an oral presentation by Bindu Varghese, PhD. This presentation is scheduled to take place on Friday, November 3, 2023, at 11:30 am PT, during Session 104: Late Breaking Abstract Session.

Carisma will also present two posters highlighting next-generation enhancements to their CAR-M platform. The first poster, titled “CAR-Macrophages with custom intronic shRNA exhibit enhanced efficacy against solid tumors,” will be presented by Chris Sloas, PhD. The second poster, titled “Engineered Microenvironment Converters (EM-C): Macrophages expressing synthetic cytokine receptors reverse immunosuppressive signals in solid tumors,” will also be presented by Chris Sloas, PhD. Both posters will be available for viewing on Friday, November 3, 2023, from 9:00 am to 7:00 pm.

Additionally, Carisma will share a trial-in-progress poster providing an overview of its Phase 1 first-in-human (FIH) study design of its lead program, CT-0508. This program involves the use of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors. The poster, titled “A Phase 1, First in Human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2 overexpressing solid tumors,” will be presented by Kim Reiss, MD.

Carisma’s presentations and posters will be available in the Journal for ImmunoTherapy of Cancer (JITC) supplement once published on Tuesday, October 31, 2023, at 9:00 am ET.

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing transformative immunotherapies for the treatment of cancer and other serious diseases. Their proprietary cell therapy platform utilizes macrophage and monocyte cell engineering to create innovative therapies. The company is headquartered in Philadelphia, PA.

For more information about Carisma and their ongoing research, please visit www.carismatx.com.

LEAVE A REPLY

Please enter your comment!
Please enter your name here